Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

As Werewolf moves toward the clinic with two lead oncology candidates and a $72 million crossover round, the company’s conditionally-activated immune modulation platform is also provoking interest from potential partners.

The Cambridge, Mass.-based biotech closed a series B round Thursday with seven new investors led by RA Capital, building on contributions from six prior investors including MPM Capital, its founding investor...